Pfizer, Johnson & Johnson Announce Discontinuation of Bapineuzumab (IV form) Studies

After failed second clinical trial, Bapineuzumab studies are dropped for patients with mild to moderate Alzheimer’s disease, as the drug was ineffective against clearing Abeta plaques in mild to moderate Alzheimer’s patients. The important consideration is to provide an Abeta clearing therapy far earlier in the disease process.  Read Wall Street Journal Article here.

 

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.